Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/136802
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: The Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A multicenter, parallel-group, open-label randomized clinical trial
Author: Poole, A.P.
Finnis, M.E.
Anstey, J.
Bellomo, R.
Bihari, S.
Birardar, V.
Doherty, S.
Eastwood, G.
Finfer, S.
French, C.J.
Heller, S.
Horowitz, M.
Kar, P.
Kruger, P.S.
Maiden, M.J.
Mårtensson, J.
McArthur, C.J.
McGuinness, S.P.
Secombe, P.J.
Tobin, A.E.
et al.
Citation: American Journal of Respiratory and Critical Care Medicine, 2022; 206(7):874-882
Publisher: American Thoracic Society
Issue Date: 2022
ISSN: 1073-449X
1535-4970
Statement of
Responsibility: 
Alexis P. Poole, Mark E. Finnis, James Anstey, Rinaldo Bellomo, Shailesh Bihari, Vishwanath Biradar, Sarah Doherty, Glenn Eastwood, Simon Finfer, Craig J. French, Simon Heller, Michael Horowitz, Palash Kar, Peter S. Kruger, Matthew J. Maiden, Johan Mårtensson, Colin J. McArthur, Shay P. McGuinness, Paul J. Secombe, Antony E. Tobin, Andrew A. Udy, Paul J. Young, and Adam M. Deane, for the LUCID Study Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG)
Abstract: Rationale: Blood glucose concentrations affect outcomes in critically ill patients, but the optimal target blood glucose range in those with type 2 diabetes is unknown. Objectives: To evaluate the effects of a “liberal” approach to targeted blood glucose range during ICU admission. Methods: This mutlicenter, parallel-group, open-label randomized clinical trial included 419 adult patients with type 2 diabetes expected to be in the ICU on at least three consecutive days. In the intervention group intravenous insulin was commenced at a blood glucose .252 mg/dl and titrated to a target range of 180–252 mg/dl. In the comparator group insulin was commenced at a blood glucose .180 mg/dl and titrated to a target range of 108–180 mg/dl. The primary outcome was incident hypoglycemia (,72 mg/dl). Secondary outcomes included glucose metrics and clinical outcomes. Measurements and Main Results: By Day 28, at least one episode of hypoglycemia occurred in 10 of 210 (5%) patients assigned the intervention and 38 of 209 (18%) patients assigned the comparator (incident rate ratio, 0.21 [95% confidence interval (CI), 0.09 to 0.49]; P,0.001). Those assigned the intervention had greater blood glucose concentrations (daily mean, minimum, maximum), less glucose variability, and less relative hypoglycemia (P,0.001 for all comparisons). By Day 90, 62 of 210 (29.5%) in the intervention and 52 of 209 (24.9%) in the comparator group had died (absolute difference, 4.6 percentage points [95% CI, 23.9% to 13.2%]; P = 0.29). Conclusions: A liberal approach to blood glucose targets reduced incident hypoglycemia but did not improve patientcentered outcomes. Clinical trial registered with Australian New Zealand Clinical Trials Registry (ACTRN 12616001135404).
Keywords: LUCID Study Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG)
blood glucose; critical illness; diabetes; hypoglycemia; intensive care
Rights: Copyright © 2022 by the American Thoracic Society
DOI: 10.1164/rccm.202202-0329oc
Published version: http://dx.doi.org/10.1164/rccm.202202-0329oc
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.